Progyny CEO Peter Anevski sells 126,204 shares

The two additional sales by Progyny's chief executive officer were made under a Rule 10b5-1 trading plan entered into July 2, 2026.

Available on EDGAR 11/09/2026 - 09:57 PM EST Accepted by SEC EDGAR 11/09/2026 - 09:57 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Progyny, Inc. Chief Executive Officer Peter Anevski exercised options for 3,400 shares on November 5, 2026, and 126,204 shares on November 9, at an exercise price of $0.91 per share; he sold the same respective share counts at weighted-average prices of $35.2276 and $35.7257.

He also sold 8,539 shares on November 5 at a weighted-average $35.0906 and 35,104 shares on November 9 at $35.7257. Those two additional sales were made under a Rule 10b5-1 trading plan entered into July 2, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 8 txns

Insider Anevski Peter

Role CHIEF EXECUTIVE OFFICER

Sold 173,247 shs ($6.18M)

Approx. gross sale proceeds $6.18M

Approx. exercise cost $118K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F5	126,204	$0.00	$0.00
Exercise	Common Stock	126,204	$0.91	$115K
Sale	Common Stock F4	126,204	$35.7257	$4.51M
Sale	Common Stock F2, F4	35,104	$35.7257	$1.25M
Exercise	Stock Option (Right to Buy) F5	3,400	$0.00	$0.00
Exercise	Common Stock	3,400	$0.91	$3K
Sale	Common Stock F1	3,400	$35.2276	$120K
Sale	Common Stock F2, F3	8,539	$35.0906	$300K

Holdings After Transaction: Stock Option (Right to Buy) — 342,503 options (Direct); Common Stock — 762,468 shares (Direct)

Footnotes (5)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. Shares sold pursuant to a Rule 10b5-1 trading plan entered into on July 2, 2026.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
5. F5. These options are fully vested and exercisable.

Key Figures

Shares acquired through option exercise: 3,400 shares Shares acquired through option exercise: 126,204 shares Common shares sold and weighted-average price: 3,400 shares; $35.2276 per share +4 more

7 metrics

Shares acquired through option exercise 3,400 shares November 5, 2026; exercise price $0.91 per share

Shares acquired through option exercise 126,204 shares November 9, 2026; exercise price $0.91 per share

Common shares sold and weighted-average price 3,400 shares; $35.2276 per share November 5, 2026; sales at prices from $35.00 to $35.32, inclusive

Common shares sold and weighted-average price 8,539 shares; $35.0906 per share November 5, 2026; sales at prices from $35.00 to $35.32, inclusive

Common shares sold and weighted-average price 126,204 shares; $35.7257 per share November 9, 2026; sales at prices from $35.00 to $35.99, inclusive

Common shares sold and weighted-average price 35,104 shares; $35.7257 per share November 9, 2026; sales at prices from $35.00 to $35.99, inclusive

Option exercise price $0.91 per share For options exercised on November 5 and November 9, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested and exercisable, Stock Option (Right to Buy)

4 terms

Rule 10b5-1 trading plan regulatory

"Shares sold pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested and exercisable technical

"These options are fully vested and exercisable"

Stock Option (Right to Buy) technical

"Stock Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What PGNY share sales did Peter Anevski report on November 5 and 9, 2026?

On November 5, 2026, he sold 3,400 shares at a weighted-average $35.2276 per share and 8,539 shares at a weighted-average $35.0906. On November 9, he sold 126,204 shares at a weighted-average $35.7257 and 35,104 shares at the same weighted-average price.

Which PGNY sales did Peter Anevski report under a Rule 10b5-1 plan?

The 8,539-share sale on November 5 and the 35,104-share sale on November 9 were reported as made under a Rule 10b5-1 trading plan entered into July 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anevski Peter

(Last) (First) (Middle)

C/O PROGYNY, INC.

1359 BROADWAY, 2ND FLOOR

(Street)

NEW YORK NEW YORK 10018

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Progyny, Inc. [ PGNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2026		M		3,400	A	$0.91	809,511	D
Common Stock	11/05/2026		S		3,400	D	$35.2276(1)	806,111	D
Common Stock	11/05/2026		S(2)		8,539	D	$35.0906(3)	797,572	D
Common Stock	11/09/2026		M		126,204	A	$0.91	923,776	D
Common Stock	11/09/2026		S		126,204	D	$35.7257(4)	797,572	D
Common Stock	11/09/2026		S(2)		35,104	D	$35.7257(4)	762,468	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.91	11/05/2026		M			3,400	(5)	08/03/2027	Common Stock	3,400	$0	468,707	D
Stock Option (Right to Buy)	$0.91	11/09/2026		M			126,204	(5)	08/03/2027	Common Stock	126,204	$0	342,503	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. Shares sold pursuant to a Rule 10b5-1 trading plan entered into on July 2, 2026.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

5. These options are fully vested and exercisable.

Remarks:

	/s/ Mark Livingston, Attorney-in-Fact	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)